EugeneR.ViscusiMD

Pain Medicine

Professor of, Anesthesiology and Perioperative Medicine, Vice Chair of Pain Medicine, Thomas Jefferson University

Dr. Viscusi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Eugene Viscusi is an anesthesiologist and pain physician in Philadelphia, PA and is affiliated with Thomas Jefferson University. He received his medical degree from Jefferson Medical College, completed residence at the University of Pennsylvania, and has been in practice since 1984. He specializes in pain medicine. He is past president of ASRA Pain Medicine and was Chair of the 2025 Annual Meeting of the American Society of Anesthesiologists bringing 13,000 attendees to Philadelphia.

University of Pennsylvania Health SystemResidency, Anesthesiology, 1982 - 1984
Main Line Health System/Lankenau Medical CenterInternship, Internal Medicine, 1981 - 1982
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1981, MD

PubMed

Letter to the editor: Is medetomidine the next perioperative substance of abuse?
Aminat Haruna, Boris Anyama, Gaurav Chauhan, Brendan Lynch, Eugene R Viscusi
Regional Anesthesia and Pain Medicine. 2025-02-19
1 citations
Emergence of xylazine as a public health threat: what does the anesthesiologist need to know for perioperative care?
Pawan K Solanki, Samir Yellapragada, Brendan Lynch, Maria Eibel, Eugene R Viscusi
Regional Anesthesia and Pain Medicine. 2025-01-07
Narrative review: Managing buprenorphine and opioid use disorder in the perioperative setting.
Lynn Kohan, Antje Barreveld, Sudheer Potru, Alaa Abd-Elsayed, Eugene R Viscusi
Pain Practice. 2025-01-01

Screen All Patients for Cannabis Use Before Surgery: GuidelineJanuary 9th, 2023
Kowa Pharmaceuticals America,Inc. Announces Publication of Phase 3 Data Supporting FDA Approval of SEGLENTIS®(Celecoxib 56-Mg and Tramadol Hydrochloride 44mg)CI-v as an Efficacious Alternative for Moderate-to-Severe Acute Pain in Appropriate PatientsJuly 19th, 2022
Introduction: How Should the Joint Surgeon Respond to the Opioid Crisis?August 13th, 2018
Join now to see all